PANTHERx® Rare Selected to Distribute Attruby™ for TTR Amyloid Cardiomyopathy Treatment
PANTHERx® Rare to Distribute Attruby™ (acoramidis)
In a groundbreaking move for the rare disease community, PANTHERx® Rare, a leading specialty pharmacy, has been selected by BridgeBio for the distribution of Attruby™ (acoramidis). This medication represents a significant advancement in the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM), a condition that affects the heart and can lead to severe health complications.
What is Attruby™?
Attruby™ is a high-affinity stabilizer of transthyretin (TTR) intended for twice-daily oral administration. This innovative treatment is specifically approved to combat ATTR-CM, a progressive disease caused by the buildup of amyloid deposits that can damage the heart's function. What sets Attruby apart is its unique design - it mimics a naturally occurring genetic
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.